Class summary at a glance.

Every drug in the Methylating Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $3.2Mcombined across class
Total Rx claims: 2K222 unique beneficiaries
Generic mfrs (active): 2across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Betaine

Brand: Cystadane · 2K Part D claims (CY24) · 222 beneficiaries · First FDA approval: 1996-10-25

2 generic mfrs 52 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $3.2M

Class share

100%

of class CY24 spend

View profile →

Leucovorin, Folic Acid, Levomefolate Magnesium, Ferrous Cysteine Glycinate, 1,2-Docosahexanoyl-Sn-Glycero-3-Phosphoserine Calcium, 1,2-Icosapentoyl-Sn-Glycero-3-Phosphoserine Calcium, Phosphatidyl Serine, Pyridoxal 5-Phosphate, Flavin Adenine Dinucleotide, Nadh, Cobamamide, Cocarboxylase (Thiamine Pyrophosphate), Magnesium Ascorbate, Zinc Ascorbate, Magnesium L-Threonate and Betaine Capsule

Brand: PaxLyte · — Part D claims (CY24) · First FDA approval: 2024-08-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Levomefolate Magnesium, Leucovorin, Folic Acid, Ferrous Cysteine Glycinate, Magnesium Ascorbate, Zinc Ascorbate, Cocarboxylase, Flavin Adenine Dinucleotide, Nadh, Pyridoxal Phosphate Anhydrous, Cobamamide, Betaine, Magnesium L-Threonate, 1,2-Docosahexanoyl-Sn-Glycero-3-Phosphoserine Calcium, 1,2-Icosapentoyl-Sn-Glycero-3-Phosphoserine Calcium, and Phosphatidyl Serine

Brand: EnBrace HR · — Part D claims (CY24) · First FDA approval: 2011-08-12

Brand-only (no generics)

Low NADAC$4.50

→

Avg plan cost$4.50

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.